Display Settings:

Format

Send to:

Choose Destination
    Blood. 2007 May 15;109(10):4392-8. Epub 2007 Feb 6.

    The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

    Source

    Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037, USA.

    Abstract

    The 8;21 translocation is a major contributor to acute myeloid leukemia (AML) of the M2 classification occurring in approximately 40% of these cases. Multiple mouse models using this fusion protein demonstrate that AML1-ETO requires secondary mutagenic events to promote leukemogenesis. Here, we show that the negative cell cycle regulator p21(WAF1) gene is up-regulated by AML1-ETO at the protein, RNA, and promoter levels. Retroviral transduction and hematopoietic cell transplantation experiments with p21(WAF1)-deficient cells show that AML1-ETO is able to promote leukemogenesis in the absence of p21(WAF1). Thus, loss of p21(WAF1) facilitates AML1-ETO-induced leukemogenesis, suggesting that mutagenic events in the p21(WAF1) pathway to bypass the growth inhibitory effect from AML1-ETO-induced p21(WAF1) expression can be a significant factor in AML1-ETO-associated acute myeloid leukemia.

    PMID:
    17284535
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC1885483
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 1
    Figure 3
    Figure 5
    Figure 2
    Figure 4

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk